Jaguar Health

FDA And EMA Approvals Will Unlock Global Market Potential

AnalystConsensusTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

18 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$28.00

92.6% undervalued

15 Aug

US$2.07

-93.0%

-1.4%

Author's Valuation

US$28.0

92.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on01 May 25

Shared on24 Apr 25

AnalystConsensusTarget has decreased future PE multiple from 0.0x to 0.0x.

AnalystConsensusTarget Fair Value

US$28.0

92.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.18%

Pharma revenue growth rate

1.09%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.32%

Calculation

US$9.53m

Earnings '28

9.31x

PE Ratio '28

US$88.77m

Market Cap '28

US$88.77m

Market Cap '28

2.24m

No. shares '28

US$39.68

Share Price '28

US$39.68 Share Price '28

Discounted to 2025 @ 12.32% p.a.

US$28.00

Fair Value '25